Conestoga Capital Advisors LLC Sells 6,167 Shares of Repligen Co. (NASDAQ:RGEN)

Conestoga Capital Advisors LLC cut its stake in Repligen Co. (NASDAQ:RGEN - Free Report) by 0.7% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 940,710 shares of the biotechnology company's stock after selling 6,167 shares during the quarter. Repligen comprises about 1.9% of Conestoga Capital Advisors LLC's holdings, making the stock its 21st largest position. Conestoga Capital Advisors LLC owned 1.68% of Repligen worth $139,996,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in RGEN. Thrivent Financial for Lutherans grew its holdings in Repligen by 240.5% during the 2nd quarter. Thrivent Financial for Lutherans now owns 601,829 shares of the biotechnology company's stock valued at $75,866,000 after buying an additional 425,061 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in Repligen by 21.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 1,370,375 shares of the biotechnology company's stock worth $172,749,000 after acquiring an additional 237,884 shares during the period. Dimensional Fund Advisors LP boosted its holdings in Repligen by 39.4% in the 2nd quarter. Dimensional Fund Advisors LP now owns 429,524 shares of the biotechnology company's stock valued at $54,149,000 after purchasing an additional 121,305 shares during the period. New York State Common Retirement Fund grew its position in shares of Repligen by 14.4% during the 3rd quarter. New York State Common Retirement Fund now owns 567,044 shares of the biotechnology company's stock valued at $84,387,000 after purchasing an additional 71,274 shares in the last quarter. Finally, BNP Paribas Financial Markets increased its holdings in shares of Repligen by 494.0% in the first quarter. BNP Paribas Financial Markets now owns 80,399 shares of the biotechnology company's stock worth $14,787,000 after purchasing an additional 66,864 shares during the period. 97.64% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, Director Anthony Hunt sold 22,191 shares of Repligen stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total value of $3,225,905.67. Following the sale, the director now owns 139,840 shares in the company, valued at $20,328,540.80. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 1.20% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on RGEN shares. Stephens restated an "overweight" rating and issued a $170.00 target price on shares of Repligen in a research note on Tuesday, July 30th. Royal Bank of Canada reiterated an "outperform" rating and set a $205.00 target price on shares of Repligen in a research report on Thursday, September 26th. Wells Fargo & Company assumed coverage on shares of Repligen in a research report on Tuesday, August 27th. They set an "overweight" rating and a $180.00 price objective on the stock. UBS Group cut their target price on shares of Repligen from $205.00 to $185.00 and set a "buy" rating for the company in a research report on Wednesday, July 31st. Finally, JPMorgan Chase & Co. raised their price target on Repligen from $190.00 to $200.00 and gave the company an "overweight" rating in a research report on Wednesday, July 31st. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $190.25.

Repligen Trading Up 3.2 %

NASDAQ:RGEN traded up $4.34 during midday trading on Friday, reaching $138.61. 463,839 shares of the stock traded hands, compared to its average volume of 659,422. The stock has a market capitalization of $7.76 billion, a P/E ratio of -3,355.91, a PEG ratio of 3.92 and a beta of 0.95. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.56 and a current ratio of 6.65. The company has a fifty day moving average of $142.20 and a 200 day moving average of $146.15. Repligen Co. has a 12 month low of $113.50 and a 12 month high of $211.13.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its earnings results on Tuesday, July 30th. The biotechnology company reported $0.33 earnings per share for the quarter, hitting analysts' consensus estimates of $0.33. Repligen had a negative net margin of 0.32% and a positive return on equity of 3.36%. The company had revenue of $154.07 million during the quarter, compared to analyst estimates of $154.11 million. During the same period in the prior year, the business posted $0.53 earnings per share. Repligen's revenue for the quarter was down 3.2% on a year-over-year basis. On average, research analysts predict that Repligen Co. will post 1.45 EPS for the current year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.